Ovarian Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

For premenopausal women with early-stage breast cancer (one group):

• Women aged 18 to 44 years old
• Women who have not yet gone through menopause
• Women who have been diagnosed with breast cancer at an early to locally advanced stage (Stage 0 to Stage III), regardless of the specific type
• Women who are about to start a specific type of chemotherapy (CMF, anthracycline-based, or taxane-based), with or without a hormonal therapy called tamoxifen
• Women who have regular menstrual cycles, with no more than one irregular period in the past year, or at least 10 natural periods in the past year (exceptions may apply for women who were recently pregnant or who use an IUD or similar long-acting contraception)

For women who have not been diagnosed with breast cancer but carry a BRCA gene mutation (another group):

• Women aged 25 to 45 years old
• Women with a confirmed BRCA gene mutation
• Women who have regular menstrual cycles (every 21 to 35 days), with no more than one irregular period in the past year, or at least 10 natural periods in the past year (exceptions may apply for women recently pregnant or using an IUD or similar long-acting contraception)

For women with breast cancer who carry a BRCA or other gene mutation, or who have no known mutation (a third group):

• Premenopausal women aged 21 to 45 with Stage 0 to Stage 3 breast cancer
• Women who have had no previous ovarian surgery or ovarian disease
• Women who have not previously had chemotherapy
• Women with regular menstrual cycles (every 21 to 35 days) and no diagnosis of polycystic ovary syndrome (a hormonal condition affecting the ovaries)
• Women who have not used hormonal contraception in the past four weeks
• Women who have undergone genetic mutation testing in line with specific medical guidelines (confirm with trial site)
• Women who will be receiving an anthracycline-based chemotherapy treatment (such as doxorubicin combined with cyclophosphamide)

Who may not be able to join:

For the early-stage breast cancer group:

• Women who have previously received any treatment for breast cancer or another cancer, such as chemotherapy, hormonal therapy, or immunotherapy
• Women who have had surgery to remove one or both ovaries, a hysterectomy, or radiation to the pelvic area
• Women who are planning to have both ovaries surgically removed within one year of finishing chemotherapy
• Women with a previously identified fertility problem, defined as being unable to conceive after one year of trying, or having needed fertility medications or assisted reproduction (such as IVF) to attempt pregnancy
• Women who have a mother, sister, or daughter who went through menopause naturally before age 40
• Women who are currently pregnant

For the unaffected BRCA mutation carrier group:

• Women who have previously received any treatment for breast cancer or another cancer, such as chemotherapy, hormonal therapy, or immunotherapy
• Women who have had surgery to remove one or both ovaries, or radiation to the pelvic area
• Women who are planning to have both ovaries surgically removed within one year
• Women with a previously identified fertility problem (as defined above)
• Women who have a mother, sister, or daughter who went through menopause naturally before age 40
• Women who are currently pregnant

For the mutation carrier, non-mutation, and control breast cancer group:

• Women who did not have genetic mutation testing, or who tested positive for mutations in more than one gene family (confirm with trial site)
• Women over the age of 42
• Women receiving a chemotherapy regimen that is not anthracycline-based (confirm with trial site)
• Women who are current smokers, defined as having smoked at least 100 cigarettes in their lifetime and currently smoking
• Women with a BMI below 18.5 or above 40

Important: Always verify eligibility with the trial site directly before applying.